[Immunostimulants--therapeutic aspects].
Diezel. W W; Volk. H D HD; Daniel. V V; Gruner. S S; Sönnichsen. N N
Key Findings
- Thymosin‑alpha‑1 is identified as an immunostimulant with known mechanisms of action
- The review suggests it may be useful for treating immunodeficiency disorders
- It mentions possible future use of thymosin‑alpha‑1 in cancer therapy
Practical Outcomes
- Thymosin‑alpha‑1 is recognized as a potential immune‑enhancer, especially for immune‑deficient or cancer patients, but the paper provides no concrete protocols or dosage guidance. Enthusiasts should treat this as background information and seek more detailed, experimental data before incorporating it into a self‑directed regimen.
Summary
The article is a review that lists thymosin‑alpha‑1 among several immune‑boosting compounds and says it could be useful for people with weak immune systems or cancer, but it doesn’t give any specific dosing or how to use it.
Abstract
A survey is given about the so far known mode of action and the therapeutic application of the following agents with immunostimulatory effects: Interleukin-2, Interferon-gamma, Tumor necrosis factor, Thymosin alpha 1, Thymopentin, Splenopentin, Thymulin, Thymostimulin, Muramyl dipeptide, Bestatin, Tuftsin and Levamisole. The treatment of patients suffering from immunodeficiency disorders and cancer with such agents seems to be possible in the near future.
Study Information
pubmed
1989